New York State Psychiatric Institute, New York, NY, USA.
New York State Psychiatric Institute, New York, NY, USA; Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
J Psychiatr Res. 2022 Nov;155:387-394. doi: 10.1016/j.jpsychires.2022.09.016. Epub 2022 Sep 21.
The DSM-5 definition of cannabis use disorder (CUD) differs from DSM-IV by combining abuse and dependence criteria (without the legal criterion) and including withdrawal and craving criteria. Information on construct validity of the DSM-5 CUD diagnosis and severity levels is lacking. This study examines the associations between DSM-5 CUD and severity classification and a set of concurrent validators. Adults with problematic substance use were recruited from two settings: a research setting in an urban medical center and a suburban inpatient addiction treatment program. Participants who reported past-year cannabis use (n = 392) were included in this study and completed a semi-structured, clinician-administered diagnostic interview. Regression models estimated the associations between binary DSM-5 CUD and severity levels with a set of validators, including cannabis use variables, psychopathology, and functional impairment. DSM-5 CUD and all severity levels were associated with cannabis use validators, including number of days used, self-reporting that cannabis use was a major problem, and greater cannabis craving. DSM-5 CUD and severe CUD were associated with other psychiatric disorders and social impairment. Findings add information about the validity of DSM-5 CUD diagnosis and severity levels, with severe CUD receiving the strongest support from its association with validators across all domains, as distinct from the mild and moderate CUD measures that were associated with cannabis-specific validators alone. Severe CUD is likely to require more intensive treatment to bolster physical, psychiatric, and social functioning, whereas the mild and moderate severity thresholds provide useful information for identifying less severe disorders for prevention and brief intervention.
DSM-5 对大麻使用障碍(CUD)的定义与 DSM-IV 不同,它将滥用和依赖标准合并在一起(没有法律标准),并包括戒断和渴求标准。关于 DSM-5 CUD 诊断和严重程度的结构效度的信息尚不清楚。本研究检查了 DSM-5 CUD 和严重程度分类与一组同时效验器之间的关联。在两个环境中从有问题的物质使用的成年人中招募参与者:城市医疗中心的研究环境和郊区住院成瘾治疗计划。报告过去一年有大麻使用的参与者(n=392)被纳入本研究,并完成了半结构化的临床医生管理的诊断访谈。回归模型估计了二元 DSM-5 CUD 与严重程度水平与一系列效验器之间的关联,包括大麻使用变量、精神病理学和功能障碍。DSM-5 CUD 和所有严重程度水平都与大麻使用效验器相关,包括使用天数、自我报告大麻使用是主要问题,以及更大的大麻渴求。DSM-5 CUD 和严重 CUD 与其他精神障碍和社会障碍相关。研究结果提供了有关 DSM-5 CUD 诊断和严重程度的有效性的信息,严重 CUD 因其与所有领域的效验器的关联而得到最强的支持,与仅与大麻特定效验器相关的轻度和中度 CUD 措施不同。严重 CUD 可能需要更密集的治疗来增强身体、精神和社会功能,而轻度和中度严重程度阈值为识别较轻的疾病提供了有用的信息,用于预防和简短干预。